Olema Oncology, Inc. Common Stock

OLMANASDAQ • USD
7.36 USD
↘ 0.20 (2.65%)AT CLOSE (03:59 PM EST)
7.37
↗ 0.01 (0.07%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
7.37
↗ 0.01 (0.07%)
🔴Market: CLOSED

Shares of Olema Oncology, Inc. Common Stock (OLMA) are trading at $7.36. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, OLMA appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Nov 16, 2026.

Open?$7.48
High?$7.73
Low?$7.08
Prev. Close?$7.56
Volume?2.1M
Avg. Volume?1.4M
VWAP?$7.30
Rel. Volume?1.55x
Bid / Ask
Bid?$6.50 × 500
Ask?$8.10 × 100
Spread?$1.60
Midpoint?$7.30
Valuation & Ratios
Market Cap?662.3M
Shares Out?87.6M
Float?63.2M
Float %?72.2%
P/E Ratio?N/A
P/B Ratio?1.80
EPS?-$2.69
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Olema Oncology Inc is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. The company's lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), is currently in two Phase 3 clinical trials. In addition, Olema is focused in developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor.
Employees
150
Market Cap
662.3M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2020-11-19
Address
780 BRANNAN STREET
SAN FRANCISCO, CA 94103
Phone: (415) 651-3316
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
38
Momentum?
23
Short Sent.?
5
Piotroski F-Score?0/9Weak
Altman Z-Score?2.07Grey
Confidence?65%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?27.10%Squeeze Risk
Short Interest?17.1M
Days to Cover?11.9
Free Float63.2M
Avg Daily Volume1.4M
Settlement Date2026-10-30
Financial Health
Current Ratio?6.12Strong
Quick Ratio?6.12Strong
Cash Ratio?0.69Adequate
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
80
1.80CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-64.0%WEAK▾
ROA?
S&P
3
-53.5%WEAK▾
Cash Flow & Enterprise
FCF?$-178443000
Enterprise Value?$617.8M
Fundamentals ratios updated end of day